AAAAAA
Results:
1-16
|
Results: 16
Authors:
Disis, ML
Schiffman, K
Citation: Ml. Disis et K. Schiffman, Issues on clinical applications of cancer vaccines, J IMMUNOTH, 24(2), 2001, pp. 104-105
Authors:
Disis, ML
Knutson, KL
McNeel, DG
Davis, D
Schiffman, K
Citation: Ml. Disis et al., Clinical translation of peptide-based vaccine trials: The HER-2/neu model, CR R IMMUN, 21(1-3), 2001, pp. 263-273
Authors:
McNeel, DG
Nguyen, LD
Ellis, WJ
Higano, CS
Lange, PH
Disis, ML
Citation: Dg. Mcneel et al., Naturally occurring prostate cancer antigen-specific T cell responses of aTh1 phenotype can be detected in patients with prostate cancer, PROSTATE, 47(3), 2001, pp. 222-229
Authors:
Knutson, KL
Schiffman, K
Disis, ML
Citation: Kl. Knutson et al., Immunization with a HER-2/neu helper peptide generates HER-2/neu CD8 T-cell immunity in cancer patients, J CLIN INV, 107(4), 2001, pp. 477-484
Authors:
McNeel, DG
Nguyen, LD
Disis, ML
Citation: Dg. Mcneel et al., Identification of T helper epitopes from prostatic acid phosphatase, CANCER RES, 61(13), 2001, pp. 5161-5167
Authors:
Disis, ML
Schiffman, K
Gooley, TA
McNeel, DG
Rinn, K
Knutson, KL
Citation: Ml. Disis et al., Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization, CLIN CANC R, 6(4), 2000, pp. 1347-1350
Authors:
Bernhard, H
Huseby, ES
Hand, SL
Lohmann, M
Batten, WY
Disis, ML
Gralow, JR
zum Buschenfelde, KHM
Ohlen, C
Cheever, MA
Citation: H. Bernhard et al., Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression, IMMUNOBIOL, 201(5), 2000, pp. 568-582
Authors:
Disis, ML
Knutson, KL
Schiffman, K
Rinn, K
McNeel, DG
Citation: Ml. Disis et al., Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer, BREAST CANC, 62(3), 2000, pp. 245-252
Authors:
McNeel, DG
Nguyen, LD
Storer, BE
Vessella, R
Lange, PH
Disis, ML
Citation: Dg. Mcneel et al., Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer, J UROL, 164(5), 2000, pp. 1825-1829
Authors:
Gaiger, A
Reese, V
Disis, ML
Cheever, MA
Citation: A. Gaiger et al., Immunity to WT1 in the animal model and in patients with acute myeloid leukemia, BLOOD, 96(4), 2000, pp. 1480-1489
Authors:
Disis, ML
Cheever, MA
Citation: Ml. Disis et Ma. Cheever, Clinical trials of HER-2/neu peptide-based vaccines, MED INTEL U, 24, 2000, pp. 143-154
Authors:
Knutson, KL
Schiffman, K
Rinn, K
Disis, ML
Citation: Kl. Knutson et al., Immunotherapeutic approaches for the treatment of breast cancer, J MAMMARY G, 4(4), 1999, pp. 353-365
Authors:
Disis, ML
Grabstein, KH
Sleath, PR
Cheever, MA
Citation: Ml. Disis et al., Generation of immunity to the HER-2/neu oncogenic protein in patients withbreast and ovarian cancer using a peptide-based vaccine, CLIN CANC R, 5(6), 1999, pp. 1289-1297
Authors:
Ward, RL
Hawkins, NJ
Coomber, D
Disis, ML
Citation: Rl. Ward et al., Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer, HUMAN IMMUN, 60(6), 1999, pp. 510-515
Authors:
Rinn, K
Schiffman, K
Otero, HO
Disis, ML
Citation: K. Rinn et al., Antigen-specific recall urticaria to a peptide-based vaccine, J ALLERG CL, 104(1), 1999, pp. 240-242
Authors:
McNeel, DG
Schiffman, K
Disis, ML
Citation: Dg. Mcneel et al., Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor, BLOOD, 93(8), 1999, pp. 2653-2659
Risultati:
1-16
|